Here’s a bold statement: the future of medicine might just hinge on the work of researchers like Molly Shoichet, a University of Toronto professor who ditched her dream of becoming a doctor to revolutionize medicine itself. But here’s where it gets controversial: is the lab bench truly more impactful than the bedside? Shoichet’s journey suggests it might be.
Molly Shoichet’s story begins with a fascination—not with stethoscopes, but with polymers. During her undergraduate years at MIT, she encountered these large molecules, composed of repeating units found in everything from proteins to plastics, and was instantly hooked. ‘I thought that was the coolest thing,’ she recalls. This moment of discovery led her to abandon medical school and dive into graduate studies in polymer science and engineering, a decision that would reshape her career—and potentially, the future of healthcare.
Today, Shoichet is a University Professor and the Pamela and Paul Austin Chair in Precision and Regenerative Medicine at U of T’s Faculty of Applied Science & Engineering. Her research focuses on hydrogels—squishy, water-absorbing polymer chains that mimic human tissue. And this is the part most people miss: these hydrogels aren’t just cool science; they’re game-changers for delivering medications, repairing damaged tissues, and even tackling blindness and spinal cord injuries. ‘Like FedEx, we work on the packaging to get the therapeutics where they need to be,’ Shoichet explains, drawing a clever analogy to highlight the precision of her work.
Take her collaboration with Cindi Morshead, for instance. Together, they’re addressing a grim reality: over 85% of stroke patients miss the narrow window for clot-busting treatment. Shoichet’s team designed an enzyme that can penetrate the brain’s injury scar, promoting repair. This innovation is now the backbone of Chase Biotherapeutics, a startup pushing this treatment forward. But here’s a thought-provoking question: Can this approach truly transform stroke recovery, or are we still years away from widespread impact?
Shoichet’s work doesn’t stop there. For 16 years, she’s been tackling retinal diseases like glaucoma and macular degeneration alongside Valerie Wallace and Derek van der Kooy. Their discoveries led to Synakis, a spinoff refining treatments using hyaluronic-based hydrogels. Another spinoff, AmacaThera, is commercializing a hydrogel-based system that could replace addictive opioids for post-operative pain management by delivering medication directly to incision sites.
Here’s where it gets even more intriguing: Shoichet is also using hydrogels to study how cancer cells invade tissues—a problem so complex it’s been called ‘unsolvable.’ ‘I’m attracted to these big problems,’ she admits, adding, ‘I think I have a certain amount of comfort with discomfort.’ This relentless curiosity has earned her induction into all three of Canada’s national academies, the Order of Canada, and numerous prestigious awards, including the Gerhard Herzberg Canada Gold Medal.
Beyond the lab, Shoichet’s leadership is equally impressive. She served as Ontario’s first (and only) chief scientist, co-launched the knowledge translation platform Research2Reality, and directs initiatives like PRiME and BioHubNet, which train the next generation of biomanufacturing experts. Her commitment to mentorship is evident in her lab, where PhD graduates’ lab coats hang like hockey jerseys in the rafters—a unique tribute to their achievements.
Former student Daniela Isaacs-Bernal, now a research engineer at Ripple Therapeutics, credits Shoichet for teaching her to synthesize complex ideas and collaborate effectively. ‘One of the things I value most is the way she taught us to communicate,’ Isaacs-Bernal says. But here’s a counterpoint: In an era of specialization, is Shoichet’s broad approach—spanning stroke, blindness, cancer, and more—too ambitious, or is it exactly what science needs?
As Shoichet enters her fourth decade at U of T, she shows no signs of slowing down. Between ballet, dog walking, and open-water swimming, she remains driven by her core belief: ‘If we in academia don’t go after the hardest challenges, nobody else will.’ So, here’s the question for you: Do you agree that academia should lead the charge on the toughest problems, or should this responsibility fall to industry or governments? Let’s spark a discussion in the comments!
